This is a single-arm, open-label, phase Ib study. In this trial, patients with Triple Negative (TN) Advanced Breast Cancer (ABC) will be treated with increasing doses of LDE225 and docetaxel to determine the MTD (Maximum Tolerated Dose), DLT (Dose Limiting Toxicity) and RP2D (Recommended Phase II Dose) of the combination.